

PHARMA R&D WEEK VIRTUAL

Conference and Expo

Connecting Pharma
R&D Innovators

June 15-17, 2021

Featured Speakers



Ann Aerts
Head, Novartis
Foundation



Mene N. Pangalos
EVP, Biopharmaceuticals
R&D, AstraZeneca



Holly Soares
Head, Precision
Medicine, VP, Pfizer



Roy Baynes
SVP & Head, Global Clinical
Development, Merck



Zhen Su
SVP, Head, Global
Oncology Franchise, EMD
Serono, Merck KGaA
Darmstadt, Germany



Elizabeth B. Somers
Sr. Director, Alzheimer's
Disease Franchise,
Eisai



Tomas Cihlar
VP, Virology,
Gilead



Stephen Rees
VP, Discovery Biology,
AstraZeneca

Conference Programs:

16th Annual
BIOMARKER
WORLD CONGRESS

11th Annual
Clinical and Translational Biomarkers

6th Annual
Liquid Biopsy and CTCs in Clinical Trials

5th Annual
Immuno-Oncology Biomarkers

19th Annual
WPC
WORLD PRECLINICAL
CONGRESS

9th Annual
Predictive Preclinical Models in Oncology

6th Annual
3D and iPS Cell Models for Drug Discovery

6th Annual
Target Validation and Phenotypic Screening

Register by May 7 & Save up to \$200!

Corporate Sponsor:



Technology Innovation Driving Pharma R&D Productivity & Efficiency

Over the last year, we have seen pharma innovation advance at an incredible pace to tackle the COVID-19 pandemic. As the need for improved productivity and efficiency in drug and biomedical R&D intensifies, pharmaceutical companies carefully choose their investment in technology innovation. Pharma R&D Week brings together thought leaders in biopharma R&D to discuss disruptive technologies and novel platforms, as well as strategies to cut costs and increase productivity. Building on the legacy of Cambridge Healthtech Institute's 19th Annual World Preclinical Congress and 16th Annual Biomarker World Congress, Pharma R&D Week brings the latest technologies in translational biomarkers, liquid biopsy, immuno-oncology biomarkers, predictive preclinical models and 3-dimensional cell models, target discovery and validation, and phenotypic screening. Join us for special sessions on big pharma's response to COVID-19, AI and digital health innovation, and precision medicine. The comprehensive 3-day program—packed with pharma and technology presentations, interactive panel discussions, and visionary keynotes—is designed to maximize collaboration and innovation. Our virtual platform provides seamless access to presentations and panel discussions, facilitated roundtables, virtual exhibit hall, one-on-one networking, and post-conference on-demand viewing... all without leaving your computer.

Limited Complimentary Passes for Big Pharma!

Employees of these companies qualify:

abbvie

Allergan

AMGEN

AstraZeneca

Bayer

biogen idec.

Boehringer
Ingelheim

Bristol-Myers Squibb

GILEAD

gsk

Johnson & Johnson
PHARMACEUTICAL RESEARCH
& DEVELOPMENT, L.L.C.

Lilly

MERCK
INVENTING FOR LIFE

NOVARTIS
MOLECULAR
BIOLOGISTICS

Novo Nordisk
Pharmatech A/S

Novo Nordisk

Pfizer

Roche

SANOFI

Takeda

teva




#PharmaWeek

PharmaWeek.com

Register Now!

Sponsorship, Exhibit, & Lead Generation Opportunities

Past Attendee Demographics



Key Benefits

Premier Sponsor (Limited Availability)

- Choice of multiple presentations, webinar, round-table moderation and other options
- Full attendee list post-event
- 15 top leads pre-conference
- 6 registrations to main conference sessions – excludes short courses
- 4 registrations with virtual expo access
- Virtual Booth with lead gen

Corporate Sponsor

- One Presentation
- Receive targeted list of leads from your track
- 4 registrations with Main Conference Access – excludes short courses
- 2 registrations with virtual expo access
- Virtual Booth with lead gen

Corporate Support Sponsor

- 3 registrations with Main Conference Access – excludes short courses
- 2 registrations with virtual expo access
- Branding as sponsor
- Virtual Booth with lead gen

Exhibit Booth

- 2 registrations with Main Conference Access – excludes short courses
- 2 registrations with virtual expo access
- Virtual Booth with lead gen
- Booth Analytics



For more information regarding exhibit and sponsorship, please contact:

Rod Eymael, Business Development Manager
781-247-6286 | reymael@healthtech.com

2019 Sample
Attendee List



#PharmaWeek

PharmaWeek.com

Register Now!

Plenary Keynote Sessions

PHARMA
R&D WEEK VIRTUAL
Conference and Expo

JUNE 15-17, 2021



JUNE 15 | IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA

11:45 PD-1 Antibodies Are Transforming Cancer Treatment as Precision Medicine Informed Mono- or Combination Therapy

Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories



12:05 pm Sponsored Presentation (Opportunity Available)

12:15 Precision Medicine Strategies: The Next Level

Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

12:35 Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories

Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.

Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany



JUNE 16 | BIG PHARMA RESPONSE TO COVID-19 PANDEMIC

12:10 AstraZeneca R&D: Turning Science into Medicine

Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca

12:30 Sponsored Presentation (Opportunity Available)

12:40 Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity

Ann Aerts, MD, Head, Novartis Foundation

1:00 Panel Discussion: Big Pharma Response to COVID-19 Pandemic

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Tomas Cihlar, PhD, Vice President, Virology, Gilead

Additional panelists to be announced

4:15 Panel Discussion: Women in Science

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:


Emilee Connors, PhD, Director, Clinical Biomarkers, Merck Oncology

Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego

Lauren Leiman, Executive Director, BloodPAC

Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh



#PharmaWeek

PharmaWeek.com

Register Now!

Plenary Keynote Sessions

PHARMA
R&D WEEK VIRTUAL
Conference and Expo

JUNE 15-17, 2021



JUNE 17 | INNOVATION FOR PHARMA R&D PRODUCTIVITY AND EFFICIENCY

12:25 Innovation in Drug Discovery

Stephen Rees, Vice President, Discovery Biology, AstraZeneca

12:45 Sponsored Presentation (Opportunity Available)

12:55 Panel Discussion: Innovation for Pharma R&D Productivity and Efficiency

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute


Panelists:

Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline

Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute

Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca

Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 15, 2021

TUESDAY, JUNE 15

BIOMARKERS FOR PRECISION MEDICINE AND COMPANION DIAGNOSTICS

9:40 am A New Decade: A New Chapter for Precision IO?

Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany

10:00 Sponsored Presentation (Opportunity Available)

10:20 Establishing the Diagnostic Pathway for Commercialization of Novel Diagnostics through Effective Therapeutic-Diagnostic Partnerships

Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.

10:40 Development of IHC Companion Diagnostics for ADCs

Charo Garrido, PhD, Director, Companion Diagnostics, Daiichi Sankyo, Inc.

11:10 Moderated Q&A: Session Wrap-Up

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

11:35 Session Break-View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA



11:45 KEYNOTE PRESENTATION: PD-1 Antibodies Are Transforming Cancer Treatment as Precision Medicine Informed Mono- or Combination Therapy
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories

12:05 pm Sponsored Presentation (Opportunity Available)



12:15 KEYNOTE PRESENTATION: Precision Medicine Strategies: The Next Level
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

12:35 Panel Discussion: Implementing Precision Medicine at Big Pharma



Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute
Panelists:

Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.
Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany

1:05 Session Break - View Our Virtual Exhibit Hall

TRANSLATIONAL BIOMARKER STRATEGIES

1:15 Approaching Biomarker Analyses from Both a Systemic and Lesion Level Perspective

Emilee Connors, PhD, Scientific Director, Medical Affairs, Merck Research Labs

1:35 Novel Safety Biomarkers: "Exploration" to "Regulatory Readiness"

Shashi Ramaiah, PhD, Executive Director, Global Head of Biomarkers, Drug Safety R&D, Pfizer, Inc.

1:55 Translational Approaches to Identify Biomarkers of Venetoclax Response in Hematologic Malignancies

Relja Popovic, PhD, Senior Scientist, AbbVie, Inc.

2:15 Sponsored Presentation (Opportunity Available)

2:35 Session Break - View Our Virtual Exhibit Hall

BIOMARKER DISCOVERY AND ASSAY DEVELOPMENT

3:05 Next-Generation Sequencing in the Cancer Clinic: Team Tissue versus Liquid

Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego

3:25 Clinical Proteomics Enters Clinical Trials: Generic GCP-Compliant Workflows for the Routine Analysis of FFPE Tissue Samples by Quantitative Mass Spectrometry

Axel Ducret, PhD, Senior Principal Scientist, Pharmaceutical Sciences, Roche Innovation Center Basel (Switzerland)

3:45 Advancements in Fluid Biomarkers to Support Clinical Trials in Alzheimer's Disease

Tom McAvoy, PhD, Associate Principal Scientist, Merck

4:05 Actionable Protein Biomarkers to Accelerate Drug Development

Evan Mills, Director, Strategic Accounts, Olink



4:35 Moderated Q&A: Session Wrap-Up

Moderator: Shashi Ramaiah, PhD, Executive Director, Global Head of Biomarkers, Drug Safety R&D, Pfizer, Inc.

Panelists:

Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego
Evan Mills, Director, Strategic Accounts, Olink

5:00 Close of Clinical and Translational Biomarkers Conference



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 15, 2021

TUESDAY, JUNE 15

TRANSLATIONAL IMMUNO-ONCOLOGY

8:00 am Cell Engagers as Anti-Cancer Therapeutics

Virna Cortez-Retamozo, PhD, Senior Principal Scientist, Oncology & Pharmacology, Sanofi

8:20 Single-Cell RNA Sequencing Reveals Evolution of Immune Landscape during Glioblastoma Progression

Alain Charest, PhD, Associate Professor, Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center

8:40 Tumor Associated Macrophages and Response to Immune Checkpoint Inhibitors

Shahram Salek-Ardakani, PhD, Senior Director, Cancer Immunology Discovery, Pfizer, Inc.

9:00 Session Break - View Our Virtual Exhibit Hall

PREDICTIVE PRECLINICAL MODELS FOR ONCOLOGY AND IMMUNO-ONCOLOGY

9:20 SCC VII as a Novel Syngeneic Tumor Model to Assess Immune Checkpoint Blockade Resistance and CD4+ T Cell Help for CD8+ Cytotoxic T Lymphocytes

Joseph S. Dolina, PhD, Senior Scientist, T Cell Immuno-Oncology, Cancer Immunology Discovery, Pfizer, Inc.

9:40 Novel Preclinical Models to Evaluate Immune Oncology Therapeutics

Vish Muthusamy, PhD, Executive Director, Center for Precision Cancer Modeling, Yale School of Medicine

10:00 Talk Title to be Announced

Speaker to be Announced

10:20 Preclinical Cancer Models as Functional Diagnostic Tools

Keith L. Ligon, MD, PhD, Director, Dana-Farber Cancer Institute Center for Patient Derived Models and Broad Institute

10:40 Cellular Coordination against Large Targets

Daniel Irimia, MD, PhD, Associate Professor, Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospitals for Children, Boston; Director, BioMEMS Core, MGH

11:10 Moderated Q&A: Session Wrap-Up

Moderator: Keith L. Ligon, MD, PhD, Director, Dana-Farber Cancer Institute Center for Patient Derived Models and Broad Institute

Panelists:

Alain Charest, PhD, Associate Professor, Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center
Joseph S. Dolina, PhD, Senior Scientist, T Cell Immuno-Oncology, Cancer Immunology Discovery, Pfizer, Inc.
Speaker to be Announced

11:35 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: IMPLEMENTING PRECISION MEDICINE AT BIG PHARMA



11:45 KEYNOTE PRESENTATION: PD-1 Antibodies Are Transforming Cancer Treatment as Precision Medicine Informed Mono- or Combination Therapy

Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories

12:05 pm Sponsored Presentation (Opportunity Available)



12:15 KEYNOTE PRESENTATION: Precision Medicine Strategies: The Next Level

Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

12:35 Panel Discussion: Implementing Precision Medicine at Big Pharma



Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.
Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.
Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 15, 2021

1:05 Session Break - View Our Virtual Exhibit Hall

PREDICTIVE CELLULAR MODELS IN ONCOLOGY: TUMOR SPHEROIDS, ORGANOID, AND CO-CULTURE MODELS

1:15 Developing Tumor Organoid and Microphysiological Systems for Preclinical Oncology Drug Development

Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline

1:35 Drug Screening with Biofabricated 3D Disease Tissue Models

Marc Ferrer, PhD, Leader, Biomolecular Screening and Probe Development, Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health (NIH)

1:55 Advances in Immune System-Organoid Co-Cultures

Robert Vries, PhD, CEO, Hubrecht Organoid Technology (HUB)

2:15 Sponsored Presentation (Opportunity Available)

2:35 Session Break - View Our Virtual Exhibit Hall

3:05 3D Cell Culture Models of Cancers to Support the Development of Mechanomedicine

Sophie A. Lelievre, PhD, DVM, LLMPH, Professor Emerita, Basic Medical Sciences, Purdue University; Senior Scientist, Institut de Cancerologie de L'Ouest

3:25 CD34+ Stem Cell Derived Human Dendritic Cells Provide a Physiologically Relevant System to Evaluate the Pharmacology of Therapeutic Molecules

Christopher Kemball, PhD, Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.

3:45 Disseminated Hematologic Cancer Models for Drug Discovery: Learnings and Applications

Courtney Andersen, PhD, Senior Scientist, Oncology R&D, AstraZeneca

4:05 High-Throughput Organotypic Multilayer Lung Tumor Model to Probe PARPi Combination Therapies

BanuPriya Sridharan, PhD, Investigator, Organoid & Cell Biology, GlaxoSmithKline

4:35 Moderated Q&A: Session Wrap-Up

Moderator: Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline

Panelists:

Courtney Andersen, PhD, Senior Scientist, Oncology R&D, AstraZeneca

Christopher Kemball, PhD, Scientist, Biochemical & Cellular Pharmacology, Genentech, Inc.

Sophie A. Lelievre, PhD, DVM, LLMPH, Professor Emerita, Basic Medical Sciences, Purdue University; Senior Scientist, Institut de Cancerologie de L'Ouest

BanuPriya Sridharan, PhD, Investigator, Organoid & Cell Biology, GlaxoSmithKline

Robert Vries, PhD, CEO, Hubrecht Organoid Technology (HUB)

5:00 Close of Predictive Preclinical Models in Oncology Conference



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 16, 2021

WEDNESDAY, JUNE 16

LIQUID BIOPSY BIOMARKERS IN DRUG DEVELOPMENT

9:00 am Application of Cell-Free DNA and RNA as Oncologic Biomarkers for Early Detection and Drug Development

Gary J. Kelloff, Special Advisor, Cancer Imaging Program, National Institutes of Health (NIH NCI)

9:20 Liquid Biopsy Investigation of Molecular Resistance Mechanisms in Advanced Breast Cancer

Cyril Ramathal, PhD, Principal Research Scientist, Pharmacogenomics & Genetic Biomarkers, AbbVie, Inc.

9:40 Session Break - View Our Virtual Exhibit Hall

10:05 Noncoding RNA Monitoring of Melanoma Patients Receiving Checkpoint Inhibitor Immunotherapy

Dave S.B. Hoon, Professor, Director Translational Research JWCi & Director, Translational Molecular Medicine & Genomic Sequencing Center, JWCi Providence Health Systems

10:25 Ultrasensitive Detection of Minimal Residual Disease

Viktor A. Adalsteinsson, PhD, Associate Director, Gerstner Center for Cancer Diagnostics, Broad Institute of MIT and Harvard

10:45 New Technologies for Low-Cost and Efficient Targeted Resequencing for Liquid Biopsy Applications

G. Mike Makrigiorgos, PhD, Professor of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School

11:05 Talk Title to be Announced

Speaker to be Announced



11:35 Moderated Q&A: Session Wrap-Up

Moderator: Gary J. Kelloff, Special Advisor, Cancer Imaging Program, National Institutes of Health (NIH NCI)

Panelists:

G. Mike Makrigiorgos, PhD, Professor of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School
Speaker to be Announced

12:00 pm Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: BIG PHARMA RESPONSE TO COVID-19 PANDEMIC



AstraZeneca

12:10 KEYNOTE PRESENTATION:

AstraZeneca R&D: Turning Science into Medicine

Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D,

12:30 Sponsored Presentation (Opportunity Available)



12:40 KEYNOTE PRESENTATION:

Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity

Ann Aerts, MD, Head, Novartis Foundation

1:00 Panel Discussion: Big Pharma Response to COVID-19 Pandemic

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:



Tomas Cihlar, PhD, Vice President, Virology, Gilead

1:30 Session Break - View Our Virtual Exhibit Hall

LIQUID BIOPSY ASSAY DEVELOPMENT AND STANDARDS

2:00 Cross-Lab Evaluation of Liquid Biopsy NGS Assays

Joshua Xu, PhD, Branch Chief for Research to Review, Division of Bioinformatics & Biostatistics, FDA NCTR

2:20 BloodPAC Consortium Update: Establishing Standards, Accelerating Data Sharing & Increasing Accessibility for Liquid Biopsy Diagnostics

Lauren Leiman, Executive Director, BloodPAC

2:40 Sponsored Presentation (Opportunity Available)

3:00 The FNIH Biomarkers Consortium ctDNA Quality Control Materials Project and Clinical Implementation of Liquid Biopsy Standards

Dana Connors, MSc, PMP, Senior Scientific Project Manager, Cancer, Foundation for the National Institutes of Health (NIH)

3:20 Validation and Implementation of a Liquid Biopsy Assay to Support NCI Clinical Studies

Chris Karlovich, PhD, Associate Director, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research



#PharmaWeek

PharmaWeek.com

Register Now!

Liquid Biopsy and CTCs in Clinical Trials

JUNE 16, 2021

3:50 Moderated Q&A: Session Wrap-Up

*Moderator: Chris Karlovich, PhD, Associate Director,
Molecular Characterization Laboratory, Frederick National
Laboratory for Cancer Research*

Panelists:

*Dana Connors, MSc, PMP, Senior Scientific Project Manager,
Cancer, Foundation for the National Institutes of Health (NIH)
Lauren Leiman, Executive Director, BloodPAC
Joshua Xu, PhD, Branch Chief for Research to Review,
Division of Bioinformatics & Biostatistics, FDA NCTR*

4:15 Panel Discussion: Women in Science



*Moderator: Julia Boguslavsky, Executive Director,
Conferences, Cambridge Healthtech Institute*

Panelists:

*Emilee Connors, PhD, Scientific Director, Medical Affairs,
Merck Research Labs
Razelle Kurzrock, MD, Director, Center for Personalized
Cancer Therapy, University of California, San Diego
Lauren Leiman, Executive Director, BloodPAC
Holly Soares, PhD, Vice President & Head, Precision
Medicine, Pfizer, Inc.
Theresa L. Whiteside, PhD, Professor, Pathology,
Immunology & Otolaryngology, University of Pittsburgh*

**4:45 Close of Liquid Biopsy and CTCs in Clinical Trials
Conference**



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 16, 2021

WEDNESDAY, JUNE 16

3D ORGAN MODELS AND MICROPHYSIOLOGICAL SYSTEMS

8:00 am Advancing Drug Discovery Using Complex 3D Human Mini-Guts

Linda A. Lieberman, PhD, Principal Scientist, Merck Exploratory Science Center

8:20 High-Throughput Human Airway Platform Technology for Modeling Coronavirus Infections

Jeffrey Borenstein, PhD, Laboratory Technical Staff, Draper Laboratory

8:40 Microphysiological Neural Disease Models for Drug Discovery

Graham Marsh, PhD, Scientist II, Translational Cell Sciences, Biogen

9:00 Understanding the Utility of Complex *in vitro* Models in Therapeutic Development

Madhu Lal-Nag, PhD, Program Lead, Research Governance Council, Office of Translational Sciences, Center for Drug Evaluation & Research, U.S. Food and Drug Administration

9:20 An NCATS Perspective: Progress and Future Applications of Tissue Chips

Passley Hargrove-Grimes, PhD, Scientific Program Manager, National Institutes of Health Tissue Chip Program, National Center for Advancing Translational Sciences

9:40 Session Break - View Our Virtual Exhibit Hall

10:05 Development and Adoption of Microphysiological Systems for Drug Safety Assessment

Kainat Khan, PhD, Senior Scientist, Oncology Safety Combinations, AstraZeneca R&D

10:25 Matrigel 3D Bioprinting of Contractile Human Skeletal Muscle Models Recapitulating Exercise and Pharmacological Responses

Hansjoerg Keller, PhD, Senior Principal Scientist, Musculoskeletal Diseases, Novartis Institutes for BioMedical Research

10:45 Assembled 3D Cultures of Human Neurons, Astrocytes, and Microglia Recapitulate Key Aspects of Human Neurodegenerative Disease

Erik Ullian, PhD, Professor, Ophthalmology, University of California, San Francisco

11:05 Talk Title to be Announced

Speaker to be Announced



11:35 Moderated Q&A: Session Wrap-Up

Moderator: Linda A. Lieberman, PhD, Principal Scientist, Merck Exploratory Science Center

Panelists:

Jeffrey Borenstein, PhD, Laboratory Technical Staff, Draper Laboratory

Passley Hargrove-Grimes, PhD, Scientific Program Manager, National Institutes of Health Tissue Chip Program, National Center for Advancing Translational Sciences

Hansjoerg Keller, PhD, Senior Principal Scientist, Musculoskeletal Diseases, Novartis Institutes for BioMedical Research

Graham Marsh, PhD, Scientist II, Translational Cell Sciences, Biogen

Speaker to be Announced

12:00 pm Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: BIG PHARMA RESPONSE TO COVID-19 PANDEMIC



12:10 KEYNOTE PRESENTATION: AstraZeneca R&D: Turning Science into Medicine

Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca

12:30 Sponsored Presentation (Opportunity Available)



12:40 KEYNOTE PRESENTATION: Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity

Ann Aerts, MD, Head, Novartis Foundation

1:00 Panel Discussion: Big Pharma Response to COVID-19 Pandemic

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:



Tomas Cihlar, PhD, Vice President, Virology, Gilead



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 16, 2021

1:30 Session Break - View Our Virtual Exhibit Hall

INDUCED PLURIPOTENT STEM CELL MODELS

2:00 hiPSC-Derived Platforms for Functional Genomics and Drug Discovery

Jamie L. Ifkovits, PhD, Scientific Leader, Functional Genomics, GlaxoSmithKline

2:20 Drug Screens of Human Induced Pluripotent Stem Cell (hiPSC) Derived Neuronal Networks on Multi-Electrode Arrays

Anne G. Bang, PhD, Director, Cell Biology, Prebys Center, Sanford Burnham Prebys Medical Discovery Institute

2:40 Sponsored Presentation (Opportunity Available)

3:00 iPSC-Based Physiological Assays to Guide Drug Reengineering to Remove Cardiotoxicity

Mark Mercola, PhD, Joan and Sanford I. Weill Scholar and Professor, Stanford Cardiovascular Institute and Department of Medicine, Stanford University

3:20 Neuromuscular Junctions in a Well

Matthias Mueller, PhD, Associate Director, Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research

3:50 Moderated Q&A: Session Wrap-Up

Moderator: Mark Mercola, PhD, Joan and Sanford I. Weill Scholar and Professor, Stanford Cardiovascular Institute and Department of Medicine, Stanford University

Panelists:

Jamie L. Ifkovits, PhD, Scientific Leader, Functional Genomics, GlaxoSmithKline

Matthias Mueller, PhD, Associate Director, Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research

4:15 Panel Discussion: Women in Science



Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Emilee Connors, PhD, Scientific Director, Medical Affairs, Merck Research Labs

Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego

Lauren Leiman, Executive Director, BloodPAC

Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.

Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh

4:45 Close of 3D and iPS Cell Models for Drug Discovery Conference



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 17, 2021

THURSDAY, JUNE 17

BIOMARKERS AND MECHANISM OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY

8:40 am Blood Biomarkers for PD-1 Inform Mechanism
Adil Daud, MD, Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

9:00 Evaluation of Clinical Response to Cancer Therapy in the Post-PD-1 Treatment Setting
Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck

9:20 Exosomes in Cancer Plasma: Potential as Biomarkers of Immune Competence and Response to Therapy
Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh

9:40 Session Break - View Our Virtual Exhibit Hall

10:05 The Role of the DNA Damage Response in Mediating Anti-Tumor Immunity
Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center

10:25 Multimodality Approach to Identifying Biomarkers of Melanoma Immunotherapy Response and Resistance
Genevieve Boland, MD, PhD, Assistant Professor, Surgery; Director, Melanoma Surgery Program, Massachusetts General Hospital

10:45 Incorporating Tissue Imaging Technologies to Inform Preclinical IO Drug Development Strategies
Darrell R. Borger, PhD, Associate Director, Translational Sciences, Head, Integrated Translational Technologies, Oncology Drug Development Unit, Takeda

11:05 Sponsored Presentation (Opportunity Available)

11:35 Moderated Q&A: Session Wrap-Up
Moderator: Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh
Panelists:
Darrell R. Borger, PhD, Associate Director, Translational Sciences, Head, Integrated Translational Technologies, Oncology Drug Development Unit, Takeda
Adil Daud, MD, Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center
Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center

12:00 pm Session Break - View Our Virtual Exhibit Hall


PLENARY KEYNOTE SESSION: INNOVATION FOR PHARMA R&D PRODUCTIVITY AND EFFICIENCY



**12:25 KEYNOTE PRESENTATION:
Innovation in Drug Discovery**
Stephen Rees, Vice President, Discovery Biology, AstraZeneca

12:45 Sponsored Presentation
(Opportunity Available)

12:55 Panel Discussion: Innovation for Pharma R&D Productivity and Efficiency



Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute
Panelists:

Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline
Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute
Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca
Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck

1:25 Session Break - View Our Virtual Exhibit Hall

PREDICTIVE BIOMARKERS IN IMMUNO- ONCOLOGY THERAPEUTIC DEVELOPMENT

1:45 Next-Generation Clinical and Exploratory Biomarkers for IO Therapies and Combinations
Mohini Rajasagi, PhD, MD, Director, Translational Oncology and Clinical Biomarkers, Oncology Clinical Research, Merck Sharpe & Dohme

2:05 Immuno-Oncology Biomarker Development within the NCTN Cooperative Groups: At the Intersection of Government, Pharma and Academia
Andrew B. Nixon, PhD, MBA, Professor of Medicine, Duke University



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 17, 2021

2:25 Biomarkers of Bispecific T Cell Engager Activity

Genevive Hernandez, PhD, Director, Clinical Biomarkers, Clinical Research and Development, IGM Biosciences

2:45 Sponsored Presentation (Opportunity Available)

3:05 Session Break - View Our Virtual Exhibit Hall

3:25 Evaluating Biomarkers of JTX-8064 (Anti-LILRB2/ILT4 mAb) to Inform Clinical Development

Johan Baeck, MD, Senior Vice President, Clinical Development and Medical Affairs, Jounce Therapeutics

3:45 Development, Clinical Results and Translational Analysis of CAR T Cell Products for Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma

John Rossi, PhD, Senior Director, Translational Medicine, Kite, a Gilead Company

4:05 Circulating Biomarkers in Early-Stage Non-Small Cell Lung Cancer

Cara Haymaker, PhD, Assistant Professor, Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

4:35 Moderated Q&A: Session Wrap-Up

Moderator: Genevive Hernandez, PhD, Director, Clinical Biomarkers, Clinical Research and Development, IGM Biosciences

Panelists:

Johan Baeck, MD, Senior Vice President, Clinical

Development and Medical Affairs, Jounce Therapeutics

Cara Haymaker, PhD, Assistant Professor, Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

Andrew B. Nixon, PhD, MBA, Professor of Medicine, Duke University

5:00 Close of Conference



#PharmaWeek

PharmaWeek.com

Register Now!

JUNE 17, 2021

THURSDAY, JUNE 17

PHENOTYPIC DRUG DISCOVERY AND HIGH-CONTENT SCREENING

8:00 am Phenotypic Screening – Balancing Throughput with Relevance

Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute

8:20 Safety De-Risking in Phenotypic Drug Discovery: Considerations & Strategies

Fabien Vincent, PhD, Research Fellow & Lead, Immunology & Inflammation, Pfizer Inc.

8:40 Success and Challenges in Small Molecule Phenotypic Screening – A Practitioner's Perspective

Nava Krishnan, PhD, Senior Scientist, Molecular Screening & Characterization, AbbVie, Inc.

9:00 Phenotypic Screening and Mechanism-of-Action Studies in Diabetes

Bridget Wagner, PhD, Director, Pancreatic Cell Biology and Metabolic Disease, Broad Institute

9:20 Advancing High-Content Phenotypic Profiling across Cell Panels Representing Heterogenous Cancers of Unmet Need

Neil Carragher, PhD, Professor, Drug Discovery & Director of Translation, University of Edinburgh; Director, Edinburgh Cancer Discovery Unit & Edinburgh Phenotypic Assay Centre

9:40 Session Break - View Our Virtual Exhibit Hall

10:05 De novo Generation of Hit-Like Molecules from Phenotypic Data Using Artificial Intelligence

Michal Pikusa, PhD, Senior Expert, Data Science, Novartis Institutes for BioMedical Research

10:25 Large-Scale Antibacterial Phenotypic Screening and Systematic Hit Triage Reveal Novel Targets and Novel Inhibitors of Established Targets

Scott S. Walker, PhD, Principal Scientist, Infectious Diseases and Vaccines Research, Merck & Co., Inc.

10:45 Fluopack Phenotypic Screening Enables Unbiased Subcellular Profiling in Drug Discovery

Hicham Mahboubi, PhD, Principal Scientist, Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research

11:05 Sponsored Presentation (Opportunity Available)

11:35 Moderated Q&A: Session Wrap-Up

Moderator: Fabien Vincent, PhD, Research Fellow & Lead, Immunology & Inflammation, Pfizer Inc.

Panelists:

Neil Carragher, PhD, Professor, Drug Discovery & Director of Translation, University of Edinburgh; Director, Edinburgh Cancer Discovery Unit & Edinburgh Phenotypic Assay Centre
 Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute

Michal Pikusa, PhD, Senior Expert, Data Science, Novartis Institutes for BioMedical Research
 Bridget Wagner, PhD, Director, Pancreatic Cell Biology and Metabolic Disease, Broad Institute

12:00 pm Session Break - View Our Virtual Exhibit Hall



PLENARY KEYNOTE SESSION: INNOVATION FOR PHARMA R&D PRODUCTIVITY AND EFFICIENCY



12:25 KEYNOTE PRESENTATION:
Innovation in Drug Discovery
 Stephen Rees, Vice President, Discovery Biology, AstraZeneca

12:45 Sponsored Presentation
 (Opportunity Available)

12:55 Panel Discussion: Innovation for Pharma R&D Productivity and Efficiency



Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline
 Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute
 Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca
 Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck



#PharmaWeek

PharmaWeek.com

[Register Now!](#)

JUNE 17, 2021

1:25 Session Break - View Our Virtual Exhibit Hall

TARGET DISCOVERY AND VALIDATION

1:45 Target Discovery Using CRISPR and Non-CRISPR Libraries

Davide Gianni, PhD, Associate Director, Functional Genomics, AstraZeneca

2:05 Functional Genomics: From Phenotypic Screening to Target Validation

Lauren Drowley, PhD, Head, Functional Genomics, UCB Pharma

2:25 TIDVal through the Looking Glass of Clinically-Integrated Phenotypic Disease Modeling

Shane Horman, PhD, Associate Director, Early Target Discovery, Takeda California, Inc.

2:45 Talk Title to be Announced

Speaker to be Announced



3:05 Session Break - View Our Virtual Exhibit Hall

3:25 Strategies and Practicals for Novel Drug Target Identification and Validation

Wensheng Xie, PhD, Scientific Leader, Novel Human Genetics Research Unit, GlaxoSmithKline

3:45 Choosing the Appropriate Cell Models and Phenotypes for Target Validation and Screening

Taosheng Chen, PhD, Full Member & Director High Throughput Bioscience Center, Chemical Biology & Therapeutics, St. Jude Children's Research Hospital

4:05 Target Validation and Identification at the Speed of Light: Emerging Technologies

Grzegorz Sienski, PhD, Associate Principal Scientist, AstraZeneca

4:35 Moderated Q&A: Session Wrap-Up

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Shane Horman, PhD, Associate Director, Early Target Discovery, Takeda California, Inc.

Wensheng Xie, PhD, Scientific Leader, Novel Human Genetics Research Unit, GlaxoSmithKline

Speaker to be Announced

5:00 Close of Conference



#PharmaWeek

PharmaWeek.com

Register Now!

PHARMA R&D WEEK **KEY** BENEFITS

VIRTUAL CONFERENCE

accessible from the comfort of your home or office

INTERACTIVE NETWORKING

with live Q&A sessions, breakout discussions, poster viewing, live chat with exhibitors, sponsors, and fellow delegates

SPONSORED TALKS

by leading technology and service providers showcasing new offerings

INSPIRING KEYNOTE PRESENTATIONS

from world-renowned experts and visionaries

RESEARCH POSTERS

engage with researchers presenting the latest in drug discovery and biopharma R&D

ON-DEMAND LIBRARY

with an archive of presentations to access on your own time

Media Partners

Official Publications

Bio-IT World **Diagnostics World**

Lead Sponsoring Publications

STAT **TheScientist**
EXPANDING LIFE. IMPROVING BIOMEDICINE

Sponsoring Publications

Review **ANTI BODY SOCIETY** **BENTHAM SCIENCE**
DDNEWS **Pharmaceutical Outsourcing**
PharmaVoice

Lead Media Partners

for Biocompare **labcompare**
The place to learn for lab equipment

Web Sponsors

Big4Bio **1st Oncology** **BioSpace**
Drug **GEN** **Genetic Engineering Biotechnology News** **genomeweb**
pharmaceuticals **SelectScience 20**



#PharmaWeek

PharmaWeek.com

Register Now!

GET INVOLVED!

Stay Connected Before June! Join Us Now for the Free Pharma R&D Webinar Series

[Click to Learn More »](#)

KEY CONTACTS

For meeting questions or suggestions, please contact:



Julia Boguslavsky, Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

For media and association partnerships, please contact:



Rich Handy, Senior Director of Marketing
Cambridge Healthtech Institute
781-972-5456 | rhandy@healthtech.com

PRESENT A VIRTUAL POSTER & SAVE \$50

**this discount does not apply to product or service providers*

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the virtual poster sessions. To ensure your poster presentation is included in the conference materials, your full submission must be received, and your registration paid in full by **May 28, 2021**.

Register and indicate that you would like to present a virtual poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract and other materials. Please see below for more information.

REASONS YOU SHOULD PRESENT YOUR RESEARCH POSTER AT THIS CONFERENCE:

- Your research will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
- Discuss your research and collaborate with other attendees during designated chat times
- Your poster presentation will be published on our conference platform
- Receive \$50 off your registration*



#PharmaWeek

PharmaWeek.com

[Register Now!](#)

REGISTRATION OPTIONS

INDIVIDUAL PRICING:

COMMERCIAL & NON PHARMA

ACADEMIC & GOVERNMENT

PHARMA

REAL-TIME VIRTUAL

(Includes Real-Time access to all Pharma R&D Week virtual conferences & event features, and On-Demand access for one year.)

EARLY REGISTRATION UNTIL MAY 7	\$899	\$399	FREE! (UNTIL MAY 7)
ADVANCE REGISTRATION UNTIL MAY 28	\$999	\$499	
STANDARD REGISTRATION AFTER MAY 28	\$1,099	\$599	

POST-EVENT ON-DEMAND (Includes post-event access to ALL conferences. Does not include Q&A sessions or networking.)

EARLY REGISTRATION UNTIL MAY 7	\$749	\$329	FREE! (UNTIL MAY 7)
ADVANCE REGISTRATION UNTIL MAY 28	\$849	\$399	
STANDARD REGISTRATION AFTER MAY 28	\$899	\$499	

GROUP PRICING:

COMMERCIAL & NON PHARMA

ACADEMIC & GOVERNMENT

PHARMA

REAL-TIME VIRTUAL

(Includes Real-Time access to all Pharma R&D Week virtual conferences & event features, and On-Demand access for one year.)

EARLY REGISTRATION UNTIL MAY 7	\$449	\$199	FREE! (UNTIL MAY 7)
ADVANCE REGISTRATION UNTIL MAY 28	\$499	\$249	
STANDARD REGISTRATION AFTER MAY 28	\$549	\$299	

POST-EVENT ON-DEMAND (Includes post-event access to ALL conferences. Does not include Q&A sessions or networking.)

EARLY REGISTRATION UNTIL MAY 7	\$379	\$179	FREE! (UNTIL MAY 7)
ADVANCE REGISTRATION UNTIL MAY 28	\$429	\$199	
STANDARD REGISTRATION AFTER MAY 28	\$449	\$249	

VISIT OUR WEBSITE FOR COMPLETE DETAILS INCLUDING GROUP DISCOUNTS AND ON-DEMAND OPTION

ALUMNI DISCOUNT:

Cambridge Healthtech Institute (CHI) appreciates your past participation at Pharma R&D Week. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

GROUP DISCOUNTS:

Discounts are available for multiple attendees from the same organization. For more information on group rates contact Uma Patel, 781-972-5447, upatel@healthtech.com.

POSTER SUBMISSION

- DISCOUNT (\$50 OFF):

Poster materials are due by May 28, 2021. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract and other materials. If you do not receive this email within 5 business days, please contact jring@healthtech.com.

*CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

*this discount does not apply to product or service providers

HOW TO REGISTER:

PharmaWeek.com

reg@healthtech.com

P: 781.972.5400 or

Toll-free in the U.S. 888.999.6288

PLEASE USE KEYCODE

WPW V

WHEN REGISTERING!